Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors
Standard
Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors. / Viehweger, Florian; Tinger, Lisa-Marie; Dum, David; Gorbokon, Natalia; Menz, Anne; Uhlig, Ria; Büscheck, Franziska; Luebke, Andreas M; Hube-Magg, Claudia; Hinsch, Andrea; Höflmayer, Doris; Fraune, Christoph; Lebok, Patrick; Weidemann, Sören; Lennartz, Maximilian; Jacobsen, Frank; Clauditz, Till S; Krech, Rainer; Krech, Till; Marx, Andreas H; Simon, Ronald; Burandt, Eike; Steurer, Stefan; Sauter, Guido; Minner, Sarah; Bernreuther, Christian.
In: ANAL CELL PATHOL, Vol. 2022, 6412148, 2022.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors
AU - Viehweger, Florian
AU - Tinger, Lisa-Marie
AU - Dum, David
AU - Gorbokon, Natalia
AU - Menz, Anne
AU - Uhlig, Ria
AU - Büscheck, Franziska
AU - Luebke, Andreas M
AU - Hube-Magg, Claudia
AU - Hinsch, Andrea
AU - Höflmayer, Doris
AU - Fraune, Christoph
AU - Lebok, Patrick
AU - Weidemann, Sören
AU - Lennartz, Maximilian
AU - Jacobsen, Frank
AU - Clauditz, Till S
AU - Krech, Rainer
AU - Krech, Till
AU - Marx, Andreas H
AU - Simon, Ronald
AU - Burandt, Eike
AU - Steurer, Stefan
AU - Sauter, Guido
AU - Minner, Sarah
AU - Bernreuther, Christian
N1 - Copyright © 2022 Florian Viehweger et al.
PY - 2022
Y1 - 2022
N2 - Progesterone receptor (PR) is a member of the nuclear/steroid hormone receptor family of ligand-dependent transcription factors. It plays an important role in reproduction and mammary gland development and has various tissue-specific effects in nonreproductive organs. In diagnostic pathology, positive PR immunostaining is used to support a diagnosis of breast or gynecologic origin in a tumor. In this study, the expression of PR was analyzed by immunohistochemistry in 18,176 (interpretable: 16,445) samples from 147 different tumor types and subtypes in a tissue microarray format. PR immunostaining was detected in 57.4% of breast tumors, 28.6% of other gynecological tumors, and 1.8% of nongynecological and nonmammary tumors. Among the group of nongynecological and nonmammary tumors, particularly high rates of PR positivity were seen in neuroendocrine tumors (54.3%) and neuroendocrine carcinomas (35.7%) of the pancreas. A comparison with clinico-pathological parameters showed that reduced PR immunostaining was significantly associated with adverse histopathological and clinical features in breast carcinoma, endometrioid endometrial carcinoma, and pancreatic neuroendocrine tumors. In summary, our analysis of 147 different tumor types for PR immunostaining provides a ranking list of tumor entities according to their prevalence of PR positivity, helps to better understand the diagnostic utility of PR, and highlights the distinct PR positivity among neuroendocrine neoplasms of pancreatic origin.
AB - Progesterone receptor (PR) is a member of the nuclear/steroid hormone receptor family of ligand-dependent transcription factors. It plays an important role in reproduction and mammary gland development and has various tissue-specific effects in nonreproductive organs. In diagnostic pathology, positive PR immunostaining is used to support a diagnosis of breast or gynecologic origin in a tumor. In this study, the expression of PR was analyzed by immunohistochemistry in 18,176 (interpretable: 16,445) samples from 147 different tumor types and subtypes in a tissue microarray format. PR immunostaining was detected in 57.4% of breast tumors, 28.6% of other gynecological tumors, and 1.8% of nongynecological and nonmammary tumors. Among the group of nongynecological and nonmammary tumors, particularly high rates of PR positivity were seen in neuroendocrine tumors (54.3%) and neuroendocrine carcinomas (35.7%) of the pancreas. A comparison with clinico-pathological parameters showed that reduced PR immunostaining was significantly associated with adverse histopathological and clinical features in breast carcinoma, endometrioid endometrial carcinoma, and pancreatic neuroendocrine tumors. In summary, our analysis of 147 different tumor types for PR immunostaining provides a ranking list of tumor entities according to their prevalence of PR positivity, helps to better understand the diagnostic utility of PR, and highlights the distinct PR positivity among neuroendocrine neoplasms of pancreatic origin.
KW - Breast Neoplasms/pathology
KW - Female
KW - Humans
KW - Immunohistochemistry
KW - Prognosis
KW - Receptors, Progesterone/metabolism
U2 - 10.1155/2022/6412148
DO - 10.1155/2022/6412148
M3 - SCORING: Journal article
C2 - 35992051
VL - 2022
JO - ANAL CELL PATHOL
JF - ANAL CELL PATHOL
SN - 2210-7177
M1 - 6412148
ER -
